EP Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$115M Buy
96,123
+15,393
+19% +$15.7M 0.44% 36
2026
Q1
$74.3M Buy
80,730
+5,452
+7% +$5.53M 0.37% 43
2025
Q4
$80.9M Buy
+75,278
New +$72M 0.42% 40
2025
Q2
$56M Buy
71,787
+2,643
+4% +$2.05M 0.37% 56
2025
Q1
$57.1M Buy
69,144
+35,207
+104% +$29.3M 0.46% 47
2024
Q4
$26.2M Buy
33,937
+105
+0.3% +$86.9K 0.21% 88
2024
Q3
$30M Buy
33,832
+2,506
+8% +$2.25M 0.26% 79
2024
Q2
$28.4M Buy
31,326
+130
+0.4% +$104K 0.3% 73
2024
Q1
$24.3M Sell
31,196
-3,960
-11% -$2.82M 0.28% 78
2023
Q4
$20.5M Buy
35,156
+9,004
+34% +$5.26M 0.26% 78
2023
Q3
$14M Buy
26,152
+19,673
+304% +$10.1M 0.22% 81
2023
Q2
$12.2M Sell
6,479
-18,546
-74% -$7.78M 0.18% 90
2023
Q1
$20.7K Sell
25,025
-565
-2% -$191K ﹤0.01% 617
2022
Q4
$9.36M Buy
25,590
+630
+3% +$223K 0.17% 89
2022
Q3
$8.07M Buy
24,960
+18,432
+282% +$5.84M 0.18% 88
2022
Q2
$2.12M Buy
6,528
+7
+0.1% +$2.1K 0.05% 189
2022
Q1
$1.87M Buy
6,521
+13
+0.2% +$3.35K 0.04% 208
2021
Q4
$1.8M Buy
6,508
+398
+7% +$101K 0.04% 199
2021
Q3
$1.41M Sell
6,110
-1,472
-19% -$363K 0.04% 200
2021
Q2
$1.74M Sell
7,582
-604
-7% -$121K 0.05% 191
2021
Q1
$1.53M Buy
8,186
+502
+7% +$98.2K 0.05% 191
2020
Q4
$1.3M Buy
7,684
+1,973
+35% +$295K 0.05% 166
2020
Q3
$845K Buy
+5,711
New +$884K 0.04% 172
2020
Q2
Sell
-6,962
Closed -$1.07M 184
2020
Q1
$966K Buy
+6,962
New +$957K 0.05% 169
2019
Q4
Sell
-7,247
Closed -$810K 426
2019
Q3
$810K Buy
7,247
+784
+12% +$87.3K 0.04% 185
2019
Q2
$716K Buy
6,463
+1,447
+29% +$170K 0.04% 165
2019
Q1
$651K Buy
5,016
+1,686
+51% +$205K 0.06% 146
2018
Q4
$385K Sell
3,330
-113
-3% -$12.6K 0.03% 193
2018
Q3
$369K Buy
+3,443
New +$344K 0.03% 201
2016
Q1
Sell
-2,733
Closed -$230K 153
2015
Q4
$230K Sell
2,733
-500
-15% -$41.5K 0.04% 131
2015
Q3
$271K Buy
3,233
+350
+12% +$29.5K 0.05% 113
2015
Q2
$241K Buy
+2,883
New +$220K 0.05% 107

Other funds holding LLY

EP Wealth Advisors's LLY Position: Q2 2026 in Review

EP Wealth Advisors increased its Eli Lilly (LLY) stake by 19% in Q2 2026, buying an estimated $15.7M and bringing the position to 96,123 shares worth $115M. The position accounts for 0.44% of the portfolio, ranked #36.

EP Wealth Advisors first reported a position in LLY in Q2 2015 and has held it in 32 quarters since. 4,598 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • EP Wealth Advisors held 96,123 shares of Eli Lilly worth $115M as of Q2 2026.
  • EP Wealth Advisors bought 15,393 Eli Lilly shares in Q2 2026, an estimated $15.7M.
  • Eli Lilly made up 0.44% of EP Wealth Advisors's portfolio in Q2 2026, its #36 holding.
  • EP Wealth Advisors first reported a position in Eli Lilly in Q2 2015 and has held it in 32 quarters since.
  • 4,598 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.